Member Info for Urraca

BMD tweeted about it on Friday.
https://twitter.com/BrokermanDaniel/status/1385534154914340864

Let's focus on the great excitement around West Newton. You'll be putting potential new investors off with all this picking over past projects.

West Newton!

https://www.guerillainvesting.co.uk/2020/02/05/west-newton-the-reality-is-its-a-billion-dollar-oil-discovery-clarification-for-the-morons/

Is where the action is at. Who cares about Colter any more. It's like punting on shares - the occasional big win makes it profitable.

It's against my rules to ever invest based on a twitter tip, or the outcome of a drill. But what the hell, rules are made to be broken, and I've made good money in the past from Dan's tips, so I'm in. Like the degenerate gambler I am, lol.

That was a fantastic RNS to steady the ship, and the sp is due a major rerate from this ridiculous level. Given this info I do wonder why GM put that ridiculous line "the Company continues to have limited visibility over future sales" in the RNS on the 9th. At least it's good that he's now changed this to "The continued development and expansion of our COVID-19 portfolio demonstrates Novacyt's ability to match the rapid evolution of SARS-CoV-2 with real-time bioinformatics surveillance and accelerated product development." Stick with this in future Graham.

I agree Lorenzo, and I also hope that the full year results will provide the catalyst. It is commonplace for the results to include forward guidance, and if that is unclear for earnings, then at least guidance on the forward strategy to build a sustainable £1bn midcap company.

I don't know if any of you are aware of it, but I've been a participant in the Biobank project since it started in 2007. I recently volunteered for their phase 2 coronavirus self-test antibody study. The kit arrived today, AbC-19, UK-RTC, Abingdon Health marked on the back as manufacturer.

We only need to match AVCT's current market cap to achieve £10 a share. That's doable.

Good to hear from DrDev. I'm sure he can confirm both that the NHS continues to waste multi-millions through poor procurement, has an overweight but ineffective management tier, and is permanently mired in a multitude of legal actions.

Don't worry DrDev, I'm not going to forecast a £54 a share future price. Not to say that couldn't happen, but it would be years away. I can say I think the SP should recover soon from these oversold levels. Some clarity on the dispute and what it means for earnings, but especially clarity on the strategy to cement NCYT as a midcap going forward will see to that. £10 is my prediction. Quite soon now.

If you look at the three month chart on the 'MHC share price' page (first tab top left), you can see quite clearly that the price has been spiking up on heavy volume, then drifting down as volume drops off. I'm sometimes honestly baffled by how very short the sticking power of a lot of PIs is. Sure it is right to cut your losses if you've made a bad call, but the trend here is clearly up. If you want to trade it, you should be selling at the peaks, and buying back around nowish.

They have said these will be provided before the end of this month. I expect more clarity on Q4 2020 revenue, the contractual dispute, but above all, some future guidance, even if it the emerging strategy. Of which we've had hints, but I want GM to paint the picture, join the dots, and inject some positivity.

It read like the HUR board releasing good news through gritted teeth

Sell then barnett, before you get a haircut

It is strange, isn't it, that the Government schedule a 7 hour Parliamentary woke fest on whether to call the way the CCP treats the Uyghur minority a genocide for next week, while at the same time shovelling £billions to China for obviously substandard products. But inconsistent really. Specially as the current pandemic started in China.

The 29 Jan RNS said they expected to announce full year results in April, so sometime in the next fortnight. I'd be very surprised if they didn't keep to this guidance. And with the full year results I would expect some sort of forward look and guidance, even if it's only bare bones of the strategy for the future.

And yet they didn't

I think a load of traders who piled in Monday and yesterday are cashing in their 10% profit. Once they've washed through we'll start rising again.

Hydr31, I appreciate what you ate saying about sales teams. This is a significant management task, of greater importance than issuing RNSes to try and massage the share price. But may I suggest that you read the R&D RNS from 24 Feb? NCYT has devoted significant resources with the aim of developing new products to stay ahead of the curve. As they did so admirably last year. And which will, of course, continue to command a premium margin. It is all part of the plan, which GM has communicated. They are not just going to sit on their hands and milk last year's product as long as they can.

Crl123, I'm afraid you are not quite right. The acquirer has to match the highest price that they themselves have paid in the previous 12 months, rather than the highest price that any single trade managed to achieve in that time. But, in my personal opinion, there isn't enough money in the world for every AIM company that punters think are going to be taken over to actually be taken over, especially at the wildly over-optimistic premiums they predict. Take-overs are actually pretty rare. And often disappoint when they do happen. I don't personally think GM is seeking to sell out yet. This is a once in a lifetime opportunity for him to build a substantial business. He's seized it with both hands, and made a hell of a job of it so far. I think he'll want to run with it a while yet.

It is also worth saying that managing this scale up is a colossal task. GM has many plates to keep spinning. The share price is a minor metric, and as he does not need to do a capital raise, of very little day to day importance. PIs are losing perspective in their incessant focus on that single metric.

Two of them net off, so there is only one actual trade. £530k though, bit of a whopper. I'm inclined to think its been worked through the day, and is probably a buy. It would explain the strong price over the last hour and a half.